ImmunoCellular Therapeutics Ltd. (IMUC) : During the past 4 weeks, traders have been relatively bearish on ImmunoCellular Therapeutics Ltd. (IMUC), hence the stock is down -20.92% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.56% relative to the S&P 500. The 4-week change in the price of the stock is -18.26% and the stock has fallen -9.62% in the past 1 week.
The stock has recorded a 20-day Moving Average of 15.8% and the 50-Day Moving Average is 20.02%. ImmunoCellular Therapeutics, Ltd. has dropped 26.27% during the last 3-month period . Year-to-Date the stock performance stands at -47.09%.
ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC): On Fridays trading session , Opening price of the stock was $0.1999 with an intraday high of $0.2191. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.188. However, the stock managed to close at $0.188, a loss of 5.95% for the day. On the previous day, the stock had closed at $0.1999. The total traded volume of the day was 1,472,675 shares.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Companys cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Companys lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.